about
Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cureEffect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosisDefining a research agenda to address the converging epidemics of tuberculosis and diabetes. Part 2: Underlying biological mechanisms.Defining a research agenda to address the converging epidemics of tuberculosis and diabetes. Part 1: Epidemiology and clinical management.Changes in Host Immune-Endocrine Relationships during Tuberculosis Treatment in Patients with Cured and Failed Treatment Outcomes.Medroxyprogesterone acetate alters Mycobacterium bovis BCG-induced cytokine production in peripheral blood mononuclear cells of contraceptive users.Clinical immunology and multiplex biomarkers of human tuberculosisMolecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatmentThe Functional Response of B Cells to Antigenic Stimulation: A Preliminary Report of Latent Tuberculosis.Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy.Genital inflammation and the risk of HIV acquisition in womenBacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB.High-throughput Identification of DNA-Encoded IgG Ligands that Distinguish Active and Latent Mycobacterium tuberculosis Infections.Regulation of expression of mammalian gonadotrophin-releasing hormone receptor genes.Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa.Excessive Cytolytic Responses Predict Tuberculosis Relapse After Apparently Successful Treatment.The contraceptive depot medroxyprogesterone acetate impairs mycobacterial control and inhibits cytokine secretion in mice infected with Mycobacterium tuberculosis.Differential expression of interleukin-4 (IL-4) and IL-4 delta 2 mRNA, but not transforming growth factor beta (TGF-beta), TGF-beta RII, Foxp3, gamma interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis treBiomarkers for TB treatment response: challenges and future strategies.Exploring alternative biomaterials for diagnosis of pulmonary tuberculosis in HIV-negative patients by use of the GeneXpert MTB/RIF assay.Distinct cytokine patterns in semen influence local HIV shedding and HIV target cell activation.Successful TB treatment induces B-cells expressing FASL and IL5RA mRNA.Relationship between female genital tract infections, mucosal interleukin-17 production and local T helper type 17 cells.Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study.Immunological biomarkers of tuberculosis.Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus.Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response.Role of ligand-dependent GR phosphorylation and half-life in determination of ligand-specific transcriptional activity.Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction.Synthetic progestins used in HRT have different glucocorticoid agonist properties.Host immune response to tuberculous meningitis.Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response.Serine residues 338 and 339 in the carboxyl-terminal tail of the type II gonadotropin-releasing hormone receptor are critical for beta-arrestin-independent internalization.Host blood RNA signatures predict the outcome of tuberculosis treatment.Predicting tuberculosis treatment outcome using metabolomics.Corrigendum: Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure.Patients with Concurrent Tuberculosis and Diabetes Have a Pro-Atherogenic Plasma Lipid Profile.A semi-automatic technique to quantify complex tuberculous lung lesions on 18F-fluorodeoxyglucose positron emission tomography/computerised tomography images.IL-22: An Underestimated Player in Natural Resistance to Tuberculosis?Corrigendum: Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure
P50
Q28391110-CB214BF1-EBC2-4551-90CD-289F4B3EB4D0Q28729980-5FAE066C-22C4-4100-8F9E-10D3C94C9BB5Q30234697-25DD0893-0226-4EDD-81CA-F8A2ABA6E9ABQ30234699-D11BAECA-A245-434A-8AB4-3DF552782F27Q33811132-F6AF44A9-BDCB-449B-A08E-403BE297426BQ34023815-6F1F1F86-79AA-4F2A-9BEF-DA0386C83D12Q35245278-4DAD49F4-4608-4BC9-BDDB-7756AE42C8F2Q35530606-698F50CD-56CC-409A-A4AD-D793D28456AFQ35981017-792EEE6D-269F-433B-AB88-5D67E7E0EAE6Q35983023-26C0721B-7CF4-458A-A12D-D2A05CED8050Q36049017-48F6F4BB-A8EF-425C-8F52-281D1A2C012CQ36100081-44E07799-718B-464B-A563-D8BD0D6C1455Q36221447-5649BE58-7EF4-4671-8514-0DE777B21050Q36256142-C4F7E864-5372-4C41-ABFC-CBBB5D87CF2EQ36376181-63A64674-FB07-4B25-982F-AE686F413320Q36440254-29B84016-0902-4C18-B053-5F0093F3A0FCQ36804689-370AEFE7-3915-4687-A838-3B611E0FCD68Q36844861-6D9587E1-E0CC-470C-B5C7-F86544BCD9EDQ37224923-8CF530A6-C40E-4195-B6CE-5A66C0A6610CQ37336296-59EA136D-AA96-451C-9CA5-C0510EF7D9ECQ37671942-1DC68B59-B6C2-46E1-B012-4A999F042ACAQ37709222-06FA5B5C-31BE-4B29-B7ED-920E3EF640C0Q37839324-79FDB48E-3524-4908-86BA-56C9593BA20AQ37843826-245BCDFE-778A-4584-A55A-507109034D0FQ37862987-5621AE1B-F339-4E05-9983-B64B4FAFC5FFQ38363794-EB29B629-69E5-4782-A87F-C1B8B6B2E7ACQ38948899-D016067A-E279-4C77-B4EB-48B384BB3382Q39691005-9FDA29CC-C089-43CB-B21F-8A6DF63EB805Q39917306-47E21265-B879-4CF2-81B7-950C7735C215Q40380927-891E1D33-FBA8-4ADF-8285-4FE2D75F01EEQ41707503-924915C2-BA98-4ED3-B9AC-4EF7D6195971Q43683108-996A246B-BC93-4692-8B28-6BBD398128F1Q44942758-B89D6221-44F1-4C7B-9D31-CB6FF4A86089Q46490054-06DE2DD5-3FF4-4E8C-953C-88A7A04D5C50Q49668458-4C199CCB-1EF4-4F83-91C6-4C7A6BF587B1Q50030194-11ED4FCF-E83F-4343-A762-415C7989AB15Q55416101-C4317931-DB46-4046-AA3E-4DC436DBAB7AQ55617317-7EA36FFD-BB69-40EE-BDB2-93B15694B82AQ57492004-95EEFC21-A97A-4F2C-8707-C88BA4C7F7E8Q57783876-63AE75CA-00BD-496D-88C6-4AC78A977F71
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Katharina Ronacher
@ast
Katharina Ronacher
@en
Katharina Ronacher
@es
Katharina Ronacher
@nl
Katharina Ronacher
@sl
type
label
Katharina Ronacher
@ast
Katharina Ronacher
@en
Katharina Ronacher
@es
Katharina Ronacher
@nl
Katharina Ronacher
@sl
prefLabel
Katharina Ronacher
@ast
Katharina Ronacher
@en
Katharina Ronacher
@es
Katharina Ronacher
@nl
Katharina Ronacher
@sl
P1053
N-9603-2016
P106
P108
P1153
24528688300
P21
P2798
P31
P3829
P496
0000-0002-6371-1462